NovoCure Q4 Loss Narrows to $0.22 EPS, Beats Estimates
NovoCure reported a Q4 adjusted loss of $0.22 per share, narrowing from a year-ago loss of $0.61 and beating the consensus loss estimate of $0.41. The company also surpassed revenue forecasts for the quarter.
1. Q4 Financial Performance
NovoCure delivered a fourth-quarter adjusted loss of $0.22 per share, significantly better than the $0.61 loss in Q4 2024 and ahead of the consensus estimate of a $0.41 loss. Revenue for the quarter came in above analyst forecasts, reflecting stronger treatment adoption and improved operating efficiencies.
Related News
ODV
Osisko Development Raises US$275M via 4.125% Convertible Notes with 25% Premium
ODV•
NVDA
Nvidia Targets $200 Billion Agentic AI Market with Vera CPU Launch
NVDA•
NVDA
Nvidia posts US$81.6B Q1 revenue, forecasts US$91B for Q2
NVDA•
NVDA
Nvidia Tops $91B Sales Forecast, Boosts Dividend and Buyback Program
NVDA•
TSM
Samsung to Grant $340,000 Average Bonus to 78,000 Chip Workers
TSM•
Sources
FFZSB